Marisa Wexler, MS, senior science writer —

A weight-based regimen for administering Soliris (eculizumab) in people with atypical hemolytic uremic syndrome (aHUS) may allow patients to reach therapeutic levels of the medication with fewer infusions, saving time and money. “We suggest to introduce this dosing schedule as the standard of care to improve therapeutic success…

Changes in platelet counts over the first two weeks on Ultomiris (ravulizumab-cwvz) in people with atypical hemolytic uremic syndrome (aHUS) may help predict the patients’ long-term response to such treatment, according to a new study. An analysis found that patients’ early platelet responses were linked to kidney improvements at…

A girl in China had atypical hemolytic uremic syndrome (aHUS) and accompanying protein-losing enteropathy (PLE), a condition in which there is an excessive loss of proteins through the gastrointestinal tract. Treatment with Soliris (eculizumab) resolved both her aHUS-related kidney disease and PLE, according to a report. “Our case…

A toddler developed atypical hemolytic uremic syndrome (aHUS) while receiving chemotherapy to treat cancer, according to a case report. It’s easy for aHUS in cancer patients undergoing chemotherapy to be missed, since its symptoms are often mistakenly assumed to be complications caused by cancer or treatment, said the…

The case of a 49-year-old man with atypical hemolytic uremic syndrome (aHUS) that manifested after he developed pancreatitis was described in a recent report. Genetic testing showed the man had a mutation in the MCP gene, a known risk factor for aHUS. The fact that he hadn’t had any…

In cases of atypical hemolytic uremic syndrome (aHUS) that develop following pregnancy and childbirth, getting an early diagnosis is important for appropriate and timely treatment and better outcomes, a case report highlights. “A prompt and accurate diagnosis is critical in these patients to initiate early treatment, which can significantly…

The case of a woman who developed atypical hemolytic uremic syndrome (aHUS) following pregnancy highlights the importance of an early diagnosis and prompt treatment of the disease. As many as 20% of aHUS cases occur in people who are pregnant or have just given birth, referred to as…

Complement-blocking medications like Soliris (eculizumab) can be effective for controlling atypical hemolytic uremic syndrome (aHUS) in patients carrying a genetic variant called the MCPggaac haplotype, a new study reports. Researchers in Southeastern Europe reviewed the cases of 14 children in the region with aHUS to determine the best…

The safety profile of Soliris (eculizumab) in real-world practice is similar to that reported in clinical trials, according to a large analysis of data from Japan. “This is the largest safety dataset on [Soliris] in Japan derived from more than 10 years of clinical experience,” the researchers wrote. “No…

Most patients and caregivers living with atypical hemolytic uremic syndrome (aHUS) prefer Ultomiris (ravulizumab-cwvz) over Soliris (eculizumab), a new study reports. The fact that Ultomiris is administered less often than Soliris was viewed as a key factor that separates the two medications and patients on Ultomiris were…